Matt Henriksen

So you're kind of already getting that growth.

But if you have an official label, I could see that growth even growing even exponentially more.

But I guess one of the questions I have is, do you need a separate clinical trial to show that benefit for the type two patients?

Yeah.

then hey if that if we're talking about that you know being proved wrong is that growth accelerates further i mean that's a good reason i'm happy to be proved wrong in that way yeah um but you know let's talk about some of the other developments then because you know um you know we've talked a lot about the eyelet for the first you know 25 30 minutes here um but

We also were talking earlier about how there's different form factors and there's a traditional pump, but there's also the on-the-body wear.

What are your developments for an on-the-body wear for those patients that prefer that kind of more discreet fit?

Now, is that one of those things, because we talked earlier about, you know, taking a few days for kind of the algorithm to learn the specific patient.

Is that reusable portion able to kind of keep that data more and be able to, you know, benefit from that, you know, machine learning advantage?

in an easier way than kind of maybe a fully disposable patch pump?

Yeah.

And so the other thing too, is because you're using the same algorithm, that kind of, you don't need to, do you need to have a new trial to support the durable, the, the, the, the on the body wear pump, or is it, are you able to go to the FDA and say, look,

We already have the algorithm.

We have this new pump that checks off the boxes compared to some of the other on the body wares that are in the market.

We don't need to have that new clinical trial.

We got a lot of alphabet soup right now going on, but yeah.

No worries.

All right.

So what is then the potential timeline to get Mint to the market?

Okay.